To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects

NCT01449188 | Completed Phase 1

• 1 other identifier: 115458
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Ondansetron, also known as Zofran, is a marketed compound used for the prevention of nausea and vomiting. This study, called a thorough QT study, will characterize the effects of a single intravenous (IV) dose of ondansetron on cardiac repolarization as compared to placebo. Moxifloxacin, a commercially available antibiotic known to cause a mild QT prolongation, will be used as a positive control and will be given orally. The cardiac repolarization will be measured by taking consecutive ECGs on a recording device known as a Holter monitor and measuring the QT interval at specified times. In addition, blood samples will also be taken at specified times and will be used to measure the amount of study medication in the body.

Conditions

Nausea and Vomiting, Chemotherapy-Induced

Keywords

ondansetron; moxifloxacin; Zofran; thorough QT study; IV

Outcome Measures

Primary Outcomes (1)

• Change in QTcF after a single dose of Ondansetron given IV over 15 minutes.

  Two doses of ondansetron willl be used, 8mg and 32mg. The change in QTcF will be time-matched, baseline adjusted and compared to placebo.

  Single dosing day at each of the 4 treatment periods with a 7-day washout between each period. The total duration of each subject's participation in the study, from screening through follow-up will be an average of 11 weeks.

Secondary Outcomes (7)

• characterize relationship between changes in ddQTc and plasma concentrations of ondansetron

  Single dosing day at each of the 4 treatment periods with a 7-day washout between each period. The total duration of each subject's participation in the study, from screening through follow-up will be an average of 11 weeks.

• characterize relationship between QT interval and plasma ondansetron

  Single dosing day at each of the 4 treatment periods with a 7-day washout between each period. The total duration of each subject's participation in the study, from screening through follow-up will be an average of 11 weeks.

• characterize the effect on QTcI and QTcB relative to placebo between the two doses of ondansetron and moxifloxacin

  Single dosing day at each of the 4 treatment periods with a 7-day washout between each period. The total duration of each subject's participation in the study, from screening through follow-up will be an average of 11 weeks.

• characterize effect on QT and HR relative to placebo of the two doses of ondansetron and moxifloxacin.

  Single dosing day at each of the 4 treatment periods with a 7-day washout between each period. The total duration of each subject's participation in the study, from screening through follow-up will be an average of 11 weeks.

• characterize the pharmacokinetics of ondansetron.

  Single dosing day at each of the 4 treatment periods with a 7-day washout between each period. The total duration of each subject's participation in the study, from screening through follow-up will be an average of 11 weeks.

Study Arms (4)

ondansetron, 8 mg IV over 15 minutes

ACTIVE COMPARATOR

the lower ondansetron IV dose will be used in one of the four treatment periods

Drug: ondansetron

ondansetron, 32 mg IV over 15 minutes

ACTIVE COMPARATOR

the higher ondansetron IV dose will be used in one of the four treatment periods

Drug: ondansetron

placebo for ondansetron, IV over 15 minutes

PLACEBO COMPARATOR

placebo for ondansetron IV dose will be used in one of the four treatment periods

Other: saline

moxifloxacin, 400mg tablet (oral)

ACTIVE COMPARATOR

moxifloxacin is known to produce mild QT prolongation and will be used in one of the four treatment periods

Drug: moxifloxacin

Interventions

ondansetron DRUG

FDA approved drug used to treat nausea and vomiting

Also known as: Zofran

ondansetron, 32 mg IV over 15 minutes; ondansetron, 8 mg IV over 15 minutes

moxifloxacin DRUG

FDA approved antibiotic commonly used as a positive control in thorough QT studies

Also known as: Avelox

moxifloxacin, 400mg tablet (oral)

saline OTHER

USP saline IV solution used as placebo for ondansetron IV.

placebo for ondansetron, IV over 15 minutes

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy adult men and women, non-smokers between 18 and 45 years of age inclusive, at the time of signing the informed consent. Every effort will be made to enrol an approximately equal number of males and females.
• Signed and dated written informed consent prior to admission to the study, which includes compliance with the requirements and restrictions listed in the consent form.
• Healthy as judged by a responsible physician, with no clinically significant abnormality identified on the medical or laboratory evaluation performed at Screening, including 12-lead ECG. A subject with a clinical abnormality or laboratory parameters outside the reference range for this age group may be included only with the approval of the GSK medical monitor.
• ALT, alkaline phosphatase and bilirubin less than or equal to 1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
• A female is eligible to enter and participate in this study if she is of: Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who either has had a hysterectomy or has had a bilateral oophorectomy (ovariectomy) or is post-menopausal defined as being amenorrhoeic for greater than or equal to 1 year with an appropriate clinical profile, e.g., age appropriate, history of vasomotor symptoms. Follicle-stimulating hormone (FSH) must be greater than or equal to 40 mIU/mL to confirm the post-menopausal state.
• If a female is of child-bearing potential, has a negative serum pregnancy test at Screening, and agrees to or has undergone one of the following: Complete abstinence from sexual intercourse from 2 weeks prior to administration of the study drug until completion of the follow-up procedures, or, bilateral tubal ligation, or have a vasectomized partner or use an intrauterine device with published data showing that expected failure rate is less than 1% per year (e.g., GynaeFix) from 2 weeks prior to administration of study drug until completion of the follow-up procedures, or, use double-barrier method \[condom or occlusive cap (diaphragm or cervical/vault caps) used with spermicidal foam/gel/cream/suppository\].
• Body Mass Index (BMI)\* in the range of 19 - 30 kg/m2 (inclusive). \*\[BMI = weight \[kg\]/(height \[m\])2\]

You may not qualify if:

• Cardiac conduction abnormalities denoted by any of the following at screening:
• QTc interval \> 450 msec; PR interval \> 240 msec or less than or equal to 110 msec; evidence of second- or third-degree atrioventricular (AV) block; pathological Q-waves (defined as Q-wave \> 40 msec or depth greater than 0.4 - 0.5 mV); evidence of ventricular pre-excitation; electrocardiographic evidence of complete left bundle branch block, right bundle branch block (RBBB), incomplete LBBB; intraventricular conduction delay with QRS duration \> 120 msec; bradycardia as defined by sinus rate \< 50 bpm.
• Any history of myocardial infarction, syncope, long-QT syndrome, cardiac arrhythmias, or a history of uncontrolled hypertension or unstable heart disease within the 6 months prior to the screening visit, or a family history of long-QT syndrome or a family history of sudden death.
• Family history of heart attack or stroke at age less than or equal to 60 years.
• Levels of potassium, magnesium, and calcium outside the normal reference range at screening.
• Clinically significant serum chemistry and complete blood count parameters outside the normal reference range at screening.
• Positive for HIV antibody, hepatitis B virus S-antigen (HbSAg) or hepatitis C (Hep C) virus antibody at screening.
• Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
• History of alcohol/drug abuse or dependence within 12 months of the study.
• History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of \>14 drinks for males or \>7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
• A positive pre-study urine test for drugs of abuse including alcohol at screening or prior to the start of dosing. A minimum list of drugs that will be screened for includes amphetamines, barbiturates, cocaine, opiates, cannabinoids, benzodiazepines, and cotinine. Subjects will be re-screened at each treatment period.
• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
• Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
• Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK medical monitor the medication will not interfere with the study procedures or compromise subject safety.
• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Austin, Texas, 78744, United States

Location

Related Links

• Results for study 115458 can be found on the GSK Clinical Study Register.

MeSH Terms

Conditions

Nausea; Vomiting

Interventions

Ondansetron; Moxifloxacin; Sodium Chloride

Condition Hierarchy (Ancestors)

Signs and Symptoms, Digestive; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Carbazoles; Indoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds, 3-Ring; Fluoroquinolones; 4-Quinolones; Quinolones; Quinolines; Chlorides; Hydrochloric Acid; Chlorine Compounds; Inorganic Chemicals; Sodium Compounds

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 29, 2011
• First Posted: October 10, 2011
• Study Start: August 16, 2011
• Primary Completion: December 19, 2011
• Study Completion: December 19, 2011
• Last Updated: November 13, 2017

Record last verified: 2017-11

Locations

US (1)